Clinical Trial

Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated January 24, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
The addition of intranasal oxymetazoline for two weeks to already instituted optimal doses of intranasal fluticasone propionate will decrease the total number of obstructive apneas and hypopneas per hour of sleep in subjects with perennial allergic or non-allergic rhinitis and mild obstructive sleep apnea who have persistent nasal congestion despite maximum doses of NGCS.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2015-12-14; most recent amendment 2025-01-21.
Status change: Not Yet Recruiting → Recruiting 2018-09-19
Trial Details
NCT Number NCT02630121
Lead Sponsor University of South Florida
Conditions Sleep Apnea, Chronic Nasal Congestion
Enrollment 52 participants
Start Date 2023-04-01
Primary Completion 2026-04 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2025-01-24